cell therapy

The report, on goals for biotechnology and biomanufacturing in the US, suggests areas of investment including multiomics, cell therapies, gene editing, and microbial genome sequencing.

The immunotherapy firm will use Caris' "Right-In-Time" clinical trial network to recruit eligible patients for a trial of its cell-based treatment, Bria-IMT.

The deal, which is subject to negotiation, will help Avalon create diagnostics for personalizing its current and future cell immunotherapy programs.